Literature DB >> 2917699

Diabetic myocardial infarction. Interaction of diabetes with other preinfarction risk factors.

D E Singer1, A W Moulton, D M Nathan.   

Abstract

To assess the effect of diabetes on outcome after acute myocardial infarction (MI), we compared a cohort of 228 type II (non-insulin-dependent) diabetic patients who had sustained acute MI with a similar number of nondiabetic patients with MI. Thirty-day mortality was greater in the diabetic group (27 vs. 17%). However, diabetic patients were older and had more cardiovascular disease before MI. Analyses accounting for such baseline risk revealed a complex effect of diabetes. The relative risk (RR) of dying from MI due to diabetes was greatest among patients with lowest baseline risk (RR 7.3) and least among those at highest baseline risk (RR 0.83). These effects were most striking with transmural MI, which was highly lethal for those with diabetes. Analyses with pulmonary edema as the endpoint support the significant risk conferred by diabetes and its interaction with baseline risk. Diabetes is a risk factor for poor outcome after MI, particularly among patients whose pre-MI cardiovascular status otherwise appears normal.

Entities:  

Mesh:

Year:  1989        PMID: 2917699     DOI: 10.2337/diab.38.3.350

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  16 in total

Review 1.  Diabetes mellitus.

Authors:  A B Johnson; R Taylor
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

Review 2.  Adiponectin: Probe of the molecular paradigm associating diabetes and obesity.

Authors:  Kakali Ghoshal; Maitree Bhattacharyya
Journal:  World J Diabetes       Date:  2015-02-15

3.  The protection conferred against ischemia-reperfusion injury in the diabetic brain by N-acetylcysteine is associated with decreased dicarbonyl stress.

Authors:  Bin Wang; Tak Yee Aw; Karen Y Stokes
Journal:  Free Radic Biol Med       Date:  2016-04-12       Impact factor: 7.376

4.  Impact of diabetes mellitus on long term survival after acute myocardial infarction in patients with single vessel disease.

Authors:  M Ishihara; H Sato; T Kawagoe; Y Shimatani; S Kurisu; K Nishioka; Y Kouno; T Umemura; S Nakamura
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

5.  Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).

Authors:  M Raikou; A McGuire; H M Colhoun; D J Betteridge; P N Durrington; G A Hitman; H A W Neil; S J Livingstone; V Charlton-Menys; J H Fuller
Journal:  Diabetologia       Date:  2007-01-31       Impact factor: 10.122

6.  QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests.

Authors:  B S Rana; P O Lim; A A O Naas; S A Ogston; R W Newton; R T Jung; A D Morris; A D Struthers
Journal:  Heart       Date:  2005-01       Impact factor: 5.994

7.  Effects of three and eight weeks oral administration of bis(maltolato)oxovanadium(IV) on plasma homocysteine and cysteine levels in streptozotocin-induced diabetic rats.

Authors:  Kishor M Wasan; Verica Risovic; Violet G Yuen; Alan Hicke; John H McNeill
Journal:  Exp Clin Cardiol       Date:  2004

Review 8.  Disease risk score as a confounder summary method: systematic review and recommendations.

Authors:  Mina Tadrous; Joshua J Gagne; Til Stürmer; Suzanne M Cadarette
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-11-21       Impact factor: 2.890

9.  Outcome and Predictors of Stent Thrombosis in the First Romanian Registry of Drug Eluting Stent (RODESINO EXTENSION).

Authors:  Claudiu Stoicescu; Vlad Vintila; Cristian Udroiu; Nicolae Florescu; Aws Dawood; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Buchar)       Date:  2013-06

10.  Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting.

Authors:  Robert J Straka; Larry Z Liu; Prafulla S Girase; Allyson DeLorenzo; Richard H Chapman
Journal:  Cardiovasc Diabetol       Date:  2009-09-26       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.